Envista
DEXIS™IS ScanFlow v.1.0.10 adds new series of guided workflows and AI enhancements to optimize the dental implant workflow.
QUAKERTOWN, PA / ACCESSWIRE / March 19, 2024 / Earlier this year, DEXIS launched its dental implant ecosystem so clinicians can manage their entire implant workflow, from diagnosis to delivery, with one integrated toolset. To enhance workflow efficiencies, DEXIS announces the release of a new intraoral scanning update, DEXIS™IS ScanFlow v.1.0.10. The update includes a new series of guided workflows, enhancements to its AI capabilities, and an integration with DEXIS Imaging Suite software version 10.
"We are excited to introduce our latest DEXIS intraoral scanning software update, aimed at boosting productivity for DEXIS software owners and implant workflows," says Brian Gooch, VP of Marketing at DEXIS. "We've made scanning fast and easy, even for more complex situations. Digital impression data is important for implant case planning, so we enable highly accurate data to be incorporated into chairside or open workflows, and easily shared with labs or colleagues."
The IS ScanFlow software update maintains high-speed scanning, user-friendly interface, precise data capture, and an open, flexible system. Early adopters have provided positive feedback, highlighting the system's ease of use and its ability to reliably capture accurate data.
Early adopters have reported positive feedback, highlighting the wide range of cases they're able to accurately capture data for:
"The DEXIS IS 3800W intraoral scanner and its predecessors have enabled me to apply digital dentistry to all my prosthetic and implant cases," says Dr. Sebastian Patzelt. "Now, with the new AI applications in DEXIS IS ScanFlow, I'm able to digitize the soft and hard tissues of the oral cavity for fixed, removable or implant cases accurately and efficiently. *"
IS ScanFlow v1.0.10 aims to maximize productivity through AI-driven tools for dentists.
The new release adds a brand-new AI Matching tool that simplifies data capture in complex situations like multiple scan bodies, full and partial edentulism.
It also includes algorithm enhancements to its Implant Scan Body AI Assist tool which automatically detects scan bodies and reduces noise in the data, corrects artifacts and enhances details - furthering the automation of precise data capture.
IS ScanFlow v 1.0.10 introduces guided dental workflows to cut manual tasks and simplify processes.
Users now have the flexibility to fill out case information before initiating scanning or after completion, thanks to the new CaseFlow Manager tool. Regardless of the chosen option, users can then move into an easy, guided workflow that automates manual processes, predicts next steps, and assists in acquiring data for the selected indication.
The brand-new Full Arch Implant workflow guides users through the data-capture workflow for a full arch case and then automatically aligns the scans in occlusion, allowing for one consolidated dataset to send to a lab or manufacturer.
IS ScanFlow v 1.0.10 also facilitates efficient lab communication by enabling users to view case progress and real-time lab status updates directly within the Patient History screen. This allows easy collaboration, reduction in delays, and timely completion of tasks.
IS ScanFlow integrates with DTX Studio™ Clinic to connect the implant workflow
"The true power of IS ScanFlow is seen when paired with the core of the DEXIS implant ecosystem-DTX Studio Clinic," says Brian Gooch, VP of Marketing at DEXIS. "Packed with smart tools and advanced algorithms, DTX Studio Clinic serves as the clinic's imaging homebase, diagnostic hub, and treatment planning navigator. It connects each step of the implant process together and now, when purchased with an intraoral scanner, comes at no extra cost.
"Implant workflow productivity can be maximized by integrating IS ScanFlow into the rest of the tools and software within the DEXIS digital ecosystem - where practices can manage an entire implant case, from diagnosis to delivery, with one integrated toolset."
To learn more about DEXIS and the latest IS ScanFlow software version, visit https://www.dexis.com.
About DEXIS
DEXIS has been a global leading brand in digital radiography for 70+ years. Today, DEXIS has brought together the most trusted brands in 3D imaging, intraoral scanning solutions, and diagnostic software to provide patients with a complete digital diagnostic solution under a brand name. Our innovative award-winning technology enhances how the patient is diagnosed, accelerates the workflow, and delivers simple treatment paths with better patient outcomes. For more information, please visit https://www.dexis.com.
*Dr. Robert Pauley is a paid consultant for DEXIS
Contact Information
Hayley Reed
Regional Marketing Director, DEXIS IOS
hayley.reed@envistaco.com
(714) 628-8533
SOURCE: DEXIS
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
